Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Bavarian Nordic A/S
  6. News
  7. Summary
    BAVA   DK0015998017

BAVARIAN NORDIC A/S

(BAVA)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-11-28 am EST
236.50 DKK   +2.43%
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
GL
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
AQ
11/23Global markets live: UBS, Apple, Nordstrom, Autodesk, Vmware...
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

09/20/2022 | 07:02am EST

Bavarian Nordic A/S announced that the board of directors has appointed Luc Debruyne as an observer to the board with the intent to nominate him for election to the board at the ordinary general meeting in March 2023, where he following the board's constitution is expected to assume the chairmanship after Gerard van Odijk, who will step down after having served for 15 years on the board. Luc Debruyne is former President Global Vaccines at GSK, a role he held for the last six years of his 27-year long tenure with the company, where he was a member of GSK's Corporate Executive Team. He is currently Professor of Practice at the University of Leuven, Faculty of Medicine, Biomedical Sciences Group and serves as non-executive director of the boards of University Hospitals UZ Leuven and Fund Plus.

He is furthermore member of the Institutional Advisory Board at VIB, the Life Sciences Board at Greenlight Biosciences Inc, and is Strategy Advisor to the CEO and Chair of the Portfolio Strategy and Management Board of CEPI. Luc Debruyne is also highly regarded as an active contributor and advisor in the global health arena with a focus on R&D and access.


ę S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
ACCENT GROUP LIMITED 2.98% 1.73 Delayed Quote.-31.22%
BAVARIAN NORDIC A/S 2.43% 236.5 Delayed Quote.-14.10%
All news about BAVARIAN NORDIC A/S
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons h..
GL
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons h..
AQ
11/23Global markets live: UBS, Apple, Nordstrom, Autodesk, Vmware...
MS
11/23Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
GL
11/23Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
GL
11/22Bavarian Nordic's Monkeypox Vaccine Shows 78% Efficacy In New UK Analysis
MT
11/22Britain says monkeypox shot offers strong 78% protection
RE
11/18Vaccines and drugs in the pipeline for RSV
RE
11/17Bavarian Nordic Wins New Supply Contract for Monkeypox Jab With EU Pandemic Response Ag..
MT
11/17EU secures up to 2 million monkeypox vaccine doses from Bavarian Nordic
RE
More news
Analyst Recommendations on BAVARIAN NORDIC A/S
More recommendations
Financials
Sales 2022 3 092 M 432 M 432 M
Net income 2022 -606 M -84,7 M -84,7 M
Net cash 2022 1 759 M 246 M 246 M
P/E ratio 2022 -27,6x
Yield 2022 -
Capitalization 16 694 M 2 331 M 2 331 M
EV / Sales 2022 4,83x
EV / Sales 2023 1,41x
Nbr of Employees 917
Free-Float 99,8%
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 236,50 DKK
Average target price 400,57 DKK
Spread / Average Target 69,4%
EPS Revisions
Managers and Directors
Paul Chaplin President & Chief Executive Officer
Henrik Neilsen Juuel Chief Financial Officer & Executive Vice President
Gerardus Wilhelmus van Odijk Chairman
Laurence de Moerlooze Chief Medical Officer & Executive Vice President
Russell Thirsk Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
BAVARIAN NORDIC A/S-14.10%2 331
JOHNSON & JOHNSON3.66%463 391
ELI LILLY AND COMPANY32.23%347 052
ABBVIE INC.17.01%282 189
PFIZER, INC.-16.05%276 231
MERCK & CO., INC.41.51%272 555